spacer
home > white papers > R&D to Product: How to Reduce Costly Scale-Up Problems - Natoli Engineering Company, Inc.
WHITE PAPERS
logo_Natoli_Engo.jpg

Natoli Engineering Company, Inc.

phone +1 636 926 8900
email info@natoli.com
web http://www.natoli.com
email 28 Research Park Circle, Saint Charles, MO 63304, US

R&D to Product: How to Reduce Costly Scale-Up Problems

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
R&D to Product: How to Reduce Costly Scale-Up Problems
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Positive results from first preclinical in-vivo studies of Affimer therapeutics


More info >>


White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>


Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement